Last reviewed · How we verify
NCT06771518
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Phase 2 trial testing Thoracic radiotherapy in Small Cell Lung Cancer in 37 participants. Currently enrolling.
15 December 2026
Quick facts
| Lead sponsor | Regina Elena Cancer Institute |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 37 |
| Start date | 15 December 2021 |
| Primary completion | 15 December 2026 |
| Estimated completion | 15 December 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Thoracic radiotherapy
- Atezolizumab 1200 mg e.v. q21 — full drug profile →
Conditions studied
- Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →
Sponsor
Regina Elena Cancer Institute
Who can join
18 and older, any sex, with Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigate the role of consolidative radiotherapy treatment at the thoraco-mediastinal level in the patient suffering from lung microcytoma - extensive disease and treated with chemo-immunotherapy with atezolizumab, in association with maintenance therapy with atezolizumab.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06771518
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Thoracic radiotherapy
Trials testing the same drug.
- NCT06869239 — Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-om · recruiting
- NCT06536868 — Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC · Phase 2 · recruiting
- NCT06354530 — A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma · Phase 2, PHASE3 · recruiting
- NCT05544149 — TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors · Phase 2 · unknown
- NCT05353257 — A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy · Phase 3 · active not recruiting
Other recruiting trials for Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
- NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
- NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting
Other Regina Elena Cancer Institute trials
Trials by the same sponsor.
- NCT07256769 — Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis · recruiting
- NCT07248878 — Pilot Study for the Generation of Cervical Cancer Organoids From Patients Undergoing Diagnostic Biopsy · recruiting
- NCT07258186 — Generation of Endometrial Carcinoma Organoids · recruiting
- NCT07018037 — Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma · recruiting
- NCT06894628 — Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06771518 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Regina Elena Cancer Institute
- Last refreshed: 13 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06771518.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing